{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T14:26:22Z","timestamp":1783347982961,"version":"3.54.6"},"reference-count":22,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Hepatocellular carcinoma (HCC) is a heterogeneous primary liver malignancy characterized by limited treatment options and low overall survival rates. Recent studies have explored the role of programmed death ligand 1 (PD-L1), tumor-associated macrophages (TAMs), and epithelial-mesenchymal transition (EMT) in modulating tumor progression and the response to immunotherapy. This study aimed to investigate the association among PD-L1 expression, TAMs, and EMT in HCC, highlighting the recently proposed immunophenotypic variant\u2014gastric-type HCCs. A retrospective cohort of 50 surgically resected HCC patients was analyzed. Immunohistochemical staining was performed for PD-L1 (clones 28-8 and 22C3), CD68 (TAMs), and EMT markers (VSIG-1, TTF-1, and vimentin). PD-L1 expression was detected in 52% of the patients and was significantly associated with high TAM counts (p &lt; 0.001). Compared with PD-L1-negative patients, those with gastric-type HCCs, which are characterized by VSIG-1 and TTF-1 co-expression and vimentin negativity, demonstrated improved survival outcomes (p = 0.03). Integration of immune and EMT profiling of tumor cells in routine diagnostics may guide prognosis and immunotherapeutic strategies in HCC. Further molecular validation is required to confirm the biological significance of the proposed gastric-type HCC immunophenotype.<\/jats:p>","DOI":"10.3390\/ijms27136048","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T13:43:14Z","timestamp":1783345394000},"page":"6048","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Programmed Death Ligand 1 (PD-L1) and Tumor-Associated Macrophages in Gastric-Type Hepatocellular Carcinoma: Prognostic Insights"],"prefix":"10.3390","volume":"27","author":[{"given":"Rita","family":"Szodorai","sequence":"first","affiliation":[{"name":"Department of Pathology, George Emil Palade University of Medicine, Pharmacy, Science and Technology, 540139 Targu Mures, Romania"},{"name":"Department of Pathology, Clinical County Emergency Hospital, 540136 Targu Mures, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0179-3378","authenticated-orcid":false,"given":"Ilona","family":"Kovalszky","sequence":"additional","affiliation":[{"name":"Department of Pathology and Experimental Cancer Research, Semmelweis University, 26. Ulloi ut, H-1085 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin","family":"Dezs\u0151","sequence":"additional","affiliation":[{"name":"Department of Pathology and Experimental Cancer Research, Semmelweis University, 26. Ulloi ut, H-1085 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3968-5118","authenticated-orcid":false,"given":"Simona","family":"Gurzu","sequence":"additional","affiliation":[{"name":"Department of Pathology, George Emil Palade University of Medicine, Pharmacy, Science and Technology, 540139 Targu Mures, Romania"},{"name":"Department of Pathology, Clinical County Emergency Hospital, 540136 Targu Mures, Romania"},{"name":"Research Center of Oncopathology and Translational Research (CCOMT), 540136 Targu Mures, Romania"},{"name":"Romanian Academy of Medical Sciences, 030167 Bucuresti, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"ref_1","first-page":"719","article-title":"Current data in clinicopathological characteristics of primary hepatic tumors","volume":"53","author":"Turdean","year":"2012","journal-title":"Rom. J. Morphol. Embryol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Li, Q., Han, J., Yang, Y., and Chen, Y. (2022). PD-1\/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1070961"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"13076","DOI":"10.1002\/cam4.5986","article-title":"Causes of death among patients with hepatocellular carcinoma in United States from 2000 to 2018","volume":"12","author":"Yang","year":"2023","journal-title":"Cancer Med."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"van Doorn, D.J., Takkenberg, R.B., and Kl\u00fcmpen, H.J. (2020). Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview. Pharmaceuticals, 14.","DOI":"10.3390\/ph14010003"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"297","DOI":"10.4174\/astr.2023.105.5.297","article-title":"Prognostic significance of programmed cell death-ligand 1 expression on immune cells and epithelial-mesenchymal transition expression in patients with hepatocellular carcinoma","volume":"105","author":"Jung","year":"2023","journal-title":"Ann. Surg. Treat. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1758835919862692","DOI":"10.1177\/1758835919862692","article-title":"Immunotherapy for hepatocellular carcinoma: Recent advances and future perspectives","volume":"11","author":"Xu","year":"2019","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Liu, S., Zhang, S., Dong, H., Jin, X., Sun, J., Zhou, H., Jin, Y., Li, Y., and Wu, G. (2024). CD63\u2009+\u2009tumor-associated macrophages drive the progression of hepatocellular carcinoma through the induction of epithelial-mesenchymal transition and lipid reprogramming. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-12472-7"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.2217\/fon.09.91","article-title":"Epithelial-mesenchymal transition in hepatocellular carcinoma","volume":"5","author":"Zulehner","year":"2009","journal-title":"Futur. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00418-021-02006-8","article-title":"Interaction between cadherins, vimentin and V-set and immunoglobulin domain containing 1 in gastric-type hepatocellular carcinoma","volume":"156","author":"Gurzu","year":"2021","journal-title":"Histochem. Cell Biol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Szodorai, R., Banias, L., Kovalszky, I., Dezs\u0151, K., Kov\u00e1cs, Z., and Gurzu, S. (2024). Gastric-Type Expression Signature in Hepatocellular Carcinoma. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25126588"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s12029-020-00394-z","article-title":"Benefits of the 8th American Joint Committee on Cancer system for hepatocellular carcinoma staging","volume":"52","author":"Satala","year":"2021","journal-title":"J. Gastrointest. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Park, D.J., Sung, P.S., Lee, G.W., Cho, S.W., Kim, S.M., Kang, B.Y., Hur, W.H., Yang, H., Lee, S.K., and Lee, S.H. (2021). Preferential expression of Programmed Death Ligand 1 Protein in tumor-associated macrophages and its potential role in immunotherapy for hepatocellular carcinoma. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094710"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet"},{"key":"ref_15","first-page":"100788","article-title":"Programmed death ligand-1 (PD-L1) clone 22C3 expression in resected colorectal cancer as companion diagnostics for immune checkpoint inhibitor therapy: A comparison study and inter-rater agreement evaluation across proposed cut-offs and predictive (TPS, CPS and IC) scores","volume":"38","author":"Lea","year":"2024","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1080\/21645515.2020.1782692","article-title":"PD-1\/PD-L1 immune checkpoint inhibitors in glioblastoma: Clinical studies, challenges and potential","volume":"17","author":"Yang","year":"2021","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e70333","DOI":"10.1002\/mco2.70333","article-title":"Epithelial-Mesenchymal Transition in Cancer: Insights into Therapeutic Targets and Clinical Implications","volume":"6","author":"Srinivasan","year":"2025","journal-title":"MedComm"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1002\/hep.30889","article-title":"Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma","volume":"71","author":"Shigeta","year":"2020","journal-title":"Hepatology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s43066-024-00310-1","article-title":"Expression of PD-L1 clones (22C3 and 28-8) in hepatocellular carcinoma: A tertiary cancer care hospital experience","volume":"14","author":"Asghar","year":"2024","journal-title":"Egypt Liver J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1200\/PO.20.00412","article-title":"Analytical Concordance of PD-L1 Assays Utilizing Antibodies From FDA-Approved Diagnostics in Advanced Cancers: A Systematic Literature Review","volume":"5","author":"Prince","year":"2021","journal-title":"JCO Precis. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/s41416-019-0466-x","article-title":"Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: The Blueprint-HCC study","volume":"120","author":"Pinato","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s00432-024-05781-8","article-title":"Combined hepatocellular-cholangiocarcinoma: From genesis to molecular pathways and therapeutic strategies","volume":"150","author":"Gurzu","year":"2024","journal-title":"J. Cancer Res. Clin. Oncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/13\/6048\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T14:02:43Z","timestamp":1783346563000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/13\/6048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":22,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["ijms27136048"],"URL":"https:\/\/doi.org\/10.3390\/ijms27136048","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]}}}